Literature DB >> 21328053

[Secondary complications of acute subarachnoid hemorrhage].

A Zimmer1, W Reith.   

Abstract

Despite further improvement of diagnostic procedures and the management of patients with acute subarachnoid hemorrhage it is still a severe clinical condition often worsened by several secondary complications after the initial bleeding. The most important and most frequent are early rehemorraging, cerebral vasospasm and the development of hydrocephalus. In addition there are many other sequelae, such as disturbances of electrolytes, seizures and the general complications of intensive care medicine which can greatly influence clinical outcome. This report provides an overview of the possible mechanisms for the development of complications, the typical temporary course and the currently available therapeutic strategies, in particular focused on the role of diagnostic imaging in early detection of these pathological conditions.

Entities:  

Mesh:

Year:  2011        PMID: 21328053     DOI: 10.1007/s00117-010-2051-4

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  28 in total

1.  Hydrocephalus: comparison of clipping and embolization in aneurysm treatment.

Authors:  H Sethi; A Moore; J Dervin; A Clifton; J E MacSweeney
Journal:  J Neurosurg       Date:  2000-06       Impact factor: 5.115

2.  Neuroendocrine dysfunction in patients recovering from subarachnoid hemorrhage.

Authors:  Vladimir Jovanovic; Sandra Pekic; Marko Stojanovic; Goran Tasic; Branko Djurovic; Ivan Soldatovic; Mirjana Doknic; Dragana Miljic; Marina Djurovic; Milica Medic-Stojanoska; Vera Popovic
Journal:  Hormones (Athens)       Date:  2010 Jul-Sep       Impact factor: 2.885

3.  Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association.

Authors:  H P Adams; T G Brott; R M Crowell; A J Furlan; C R Gomez; J Grotta; C M Helgason; J R Marler; R F Woolson; J A Zivin
Journal:  Stroke       Date:  1994-09       Impact factor: 7.914

4.  Acute hydrocephalus following aneurysmal subarachnoid hemorrhage.

Authors:  V Mehta; R O Holness; K Connolly; S Walling; R Hall
Journal:  Can J Neurol Sci       Date:  1996-02       Impact factor: 2.104

5.  Hyperemia following aneurysmal subarachnoid hemorrhage: incidence, diagnosis, clinical features, and outcome.

Authors:  Ralf Dirk Rothoerl; Chris Woertgen; Alexander Brawanski
Journal:  Intensive Care Med       Date:  2004-04-09       Impact factor: 17.440

Review 6.  Calcium antagonists for aneurysmal subarachnoid haemorrhage.

Authors:  G J Rinkel; V L Feigin; A Algra; M Vermeulen; J van Gijn
Journal:  Cochrane Database Syst Rev       Date:  2002

7.  Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage. Correlation with cerebral vasospasm, delayed ischemic neurological deficits, and volume of hematoma.

Authors:  V Seifert; B M Löffler; M Zimmermann; S Roux; D Stolke
Journal:  J Neurosurg       Date:  1995-01       Impact factor: 5.115

Review 8.  Cerebral vasospasm after subarachnoid hemorrhage.

Authors:  Nazli Janjua; Stephan A Mayer
Journal:  Curr Opin Crit Care       Date:  2003-04       Impact factor: 3.687

9.  Medical complications of aneurysmal subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants of the Multicenter Cooperative Aneurysm Study.

Authors:  N J Solenski; E C Haley; N F Kassell; G Kongable; T Germanson; L Truskowski; J C Torner
Journal:  Crit Care Med       Date:  1995-06       Impact factor: 7.598

10.  International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion.

Authors:  Andrew J Molyneux; Richard S C Kerr; Ly-Mee Yu; Mike Clarke; Mary Sneade; Julia A Yarnold; Peter Sandercock
Journal:  Lancet       Date:  2005 Sep 3-9       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.